Scandinavian Journal of Immunology · 2020 · 20 citations · 37 references
Veterinary MedicineImmunologyPathologyCellular PathologyImmunopathologyInflammationCell-mediated ImmunityHistiocytic DisordersImmune Cell SignalingImmune-mediated Inflammatory DiseasesInflammatory Cell ResponsesInflammatory PathologyBraf V600 MutationsBraf V600e MutationCytotoxic T Lymphocyte InfiltrationImmune Microenvironment AnalysisImmunohistochemical MarkersImmunohistochemical StainingMapk Pathway MutationsTissue Infiltration By Inflammatory Cells
and MAP2K1. Some studies suggest that LCH cells can recruit and modulate inflammatory cells, which could provide reciprocal survival signals. To characterize the immune profile of infiltrating inflammatory cells, and to clarify their participation in LCH pathogenesis, a detailed immunohistochemical analysis was performed. Fifteen (10 children, 5 adults) LCH cases were assessed through macrophage (CD68 and CD163), mature dendritic cell (mDC; CD83 and CD208), regulatory T cell (Treg; CD4, CD25 and FOXP3) and cytotoxic lymphocyte (CL; CD56, CD57, perforin and granzyme B) immunomarkers. Moreover, lymphocytic and LCH markers were also analysed. All cases were S100, CD1a, CD207 and CD4-positive. Bcl-2 and cyclin D1 expression was observed in 13 of 15 cases. In the immune microenvironment, M2-polarized macrophages and Tregs were the predominant cell populations, followed by significantly (P < .005) smaller levels of mDCs and CLs. Additionally, the number of CD3 + cells was significantly higher than that of CD20 + cells. In the CD3 + cell population, there were a significantly higher number of CD4 + cells than CD8 + cells. While there were no differences when comparing the paediatric and adult populations, FOXP3 + cells were significantly higher in patients with multisystem involvement and treated with chemotherapy, than single-site cases and those without chemotherapy. Our results suggest that M2-polarized macrophages and Treg infiltration can promote LCH development and survival, probably through pro-tumoral, immunosuppressive and/or cytokine-mediated mechanisms. This work highlights the need for further exploration of immune-targeted therapy for LCH.
37
Recurrent BRAF mutations in Langerhans cell histiocytosis
Gayane Badalian‐Very, Jo‐Anne Vergilio, Barbara Degar et al. · Blood · 2010 · 1.2K citations
High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosis
Noah A. Brown, Larissa V. Furtado, Bryan L. Betz et al. · Blood · 2014 · 367 citations · Full text